Ricky Madison is a pharmaceutical scientist and computational oncologist working at the intersection of drug development, oncology, and artificial intelligence. He has led an independent R&D programme in formulation science and oncology drug discovery for over ten years. Through Medwra, his formulation R&D platform, he has delivered 35+ commercialised softgel products with zero quality failures, supporting 290%+ year-on-year growth in commercial volume. In oncology discovery, he is the founder of Oncivra, an end-to-end computational discovery platform for the TP53 Y163C cancer mutation, built around the 1.65 Å mutant crystal structure (PDB 8QWL). The platform combines generative molecule design, structure-based pocket discovery, docking, independent Boltz-2 affinity estimation, and ADMET and developability triage, narrowing a 124-molecule campaign to six computationally prioritised candidates for experimental validation. He is also the inventor of Oncyra (Irish patent application S2026/0392), a platform for mutation-aware TP53 structural modelling and drug rescue prediction across thousands of variants, supported by a suite of research applications including the P53 Atlas, Y163C Atlas, DynaPocket, PhenoRescue AI, LNPredict, and MediSynic.
University of Limerick
Limerick, Ireland
Pharmaceutical Scientist
Royal Pharmaceutical Society, London, UK
Partner Scientist
Royal Society of Chemistry, London, UK